91禁在线看 I 最近最好的2019中文 I 国产一级二级三级 I 亚洲成人av在线播放 I 91视频麻豆 I 国产999精品 I yy6080午夜 I 免费看黄色小视频 I 人妻av一区二区 I 美女羞羞动态图 I 免费日皮视频 I 黄色免费网页 I 动漫3d精品一区二区三区乱码 I 美女扒开粉嫩尿口 I 日韩av一区二区在线播放 I 欧美激情18p I 一级色网站 I 久久久男人的天堂 I 国产精品香蕉国产 I 狠狠插影院 I 亚洲成人一级 I 在线免费观看日韩视频 I 免费公开在线视频 I 午夜寂寞自拍 I 日韩国产91 I 久久不卡 I 日本激情一区 I 夜色福利

一.產品名稱：

通用名稱：大/小鼠成纖維細胞生長因子23 ELISA試劑盒

英文名稱：Mouse/Rat FGF-23 ELISA Kit

二.Mouse FGF-23 ELISA介紹：

Mouse/Rat FGF-23 ELISA Kit is intended for research use only in the quantitative determination of Mouse FGF-23 levels in serum, plasma or cell culture media. This assay is also useful in the determination of Rat FGF-23 levels.
 

Fibroblast growth factor 23 (FGF-23) is a recently discovered, novel member of a large family of related proteins. Its gene encodes a 251 amino acid protein. The amino-terminal portion of FGF-23 (aa 1-24) is hydrophobic and is likely to serve as a signal peptide allowing its secretion into the blood circulation. Its carboxyl-terminal portion (aa 180-251) shares only limited amino acid homology with other members of the FGF family of proteins.

Renal phosphate wasting disorders leading to hypophosphatemia are among the causes of defective mineralization of bone and growth plate development. Autosomal dominant hypophosphatemic rickets (ADHR), a rare genetic disorder, results from one of several different FGF-23 mutations that make the protein resistant to proteolytic cleavage. Furthermore, tumors that cause oncogenic osteomalacia (OOM) have been shown to overexpress FGF-23 mRNA making it likely that elevated concentrations of FGF-23 in the blood are the cause of renal phosphate wasting. Consistent with this conclusion, the administration of recombinant FGF-23 to rodents was shown to increase urinary excretion of phosphate thus leading to hypophosphatemia and osteomalacia/rickets. Recent studies with chronic kidney disease (CKD) patients have shown FGF-23 to be an early predictor of abnormal renal tubular function, bone mineralization, disease progression and over-all mortality risk.

Taken together, all currently available data suggest that the measurement of FGF-23 levels may provide an important diagnostic tool for the evaluation of hypophosphatemic and hyperphosphatemic disorders.
 

如需了解更多產品，請北京科瑞美公司。